Title:
ANTI-IGF-1 RECEPTOR HUMANIZED ANTIBODY
Document Type and Number:
WIPO Patent Application WO/2021/246413
Kind Code:
A1
Abstract:
Provided are: an anti-IGF-1 receptor humanized antibody which includes CDRs of a light chain and a heavy chain derived from mice parent antibody IGF11-16, and respective FRs of a light chain and a heavy chain derived from a human antibody, and in which at least one of the CDRs includes at least one amino acid residue substitution with respect to a corresponding CDR of the mice parent antibody; a fragment of the anti-IGF-1 receptor humanized antibody; or a derivative thereof.
Inventors:
MATSUKAWA HIROAKI (JP)
EGUCHI HIROSHI (JP)
NAMIKI NAOKO (JP)
TANOKURA AKIRA (JP)
EGUCHI HIROSHI (JP)
NAMIKI NAOKO (JP)
TANOKURA AKIRA (JP)
Application Number:
PCT/JP2021/020890
Publication Date:
December 09, 2021
Filing Date:
June 01, 2021
Export Citation:
Assignee:
TEIJIN PHARMA LTD (JP)
International Classes:
C12N15/13; A61K31/7088; A61K39/395; A61K48/00; A61P21/00; A61P35/00; C07K16/28; C07K16/46; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/63; C12P21/08
Domestic Patent References:
| WO2018221521A1 | 2018-12-06 | |||
| WO2019156565A1 | 2019-08-15 | |||
| WO2019152571A1 | 2019-08-08 | |||
| WO2019175186A1 | 2019-09-19 | |||
| WO2020116398A1 | 2020-06-11 | |||
| WO2018221521A1 | 2018-12-06 |
Foreign References:
| JP2020508666A | 2020-03-26 | |||
| JP2015516985A | 2015-06-18 |
Other References:
HUMAN SOMATOMEDIN C: "Somazon Formulation for Injection 10mg", May 2015, article "Drug interview form"
ABUZZAHAB, M.J. ET AL.: "IGF-1 receptor mutations resulting in intrauterine and postnatal growth retardation", N ENGL J MED, vol. 349, no. 23, 2003, pages 2211 - 22
WOODS, K.A. ET AL.: "Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene", N ENGL J MED, vol. 335, no. 18, 1996, pages 1363 - 7
MUSARO, A. ET AL.: "Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle", NATURE GENETICS, vol. 27, no. 2, 2001, pages 195 - 200, XP001199471, DOI: 10.1038/84839
XIONG, L. ET AL.: "Growth-stimulatory monoclonal antibodies against human insulin-like growth factor I receptor", PROC NATL ACAD SCI USA, vol. 89, no. 12, 1992, pages 5356 - 60, XP002423617, DOI: 10.1073/pnas.89.12.5356
RUNNELS, H.A. ET AL.: "Human monoclonal antibodies to the insulin-like growth factor 1 receptor inhibit receptor activation and tumor growth in preclinical studies", ADV THER, vol. 27, no. 7, 2010, pages 458 - 75, XP002751208, DOI: 10.1007/s12325-010-0026-5
SOOS, M.A. ET AL.: "A panel of monoclonal antibodies for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity", J BIOL CHEM, vol. 267, no. 18, 1992, pages 12955 - 63, XP002477383
KATO, H. ET AL.: "Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-1) receptor. Characterization of kinase-deficient IGF-1 receptors and the action of an IGF-1-mimetic antibody (alpha IR-3).", J BIOL CHEM, vol. 268, no. 4, 1993, pages 2655 - 61, XP008114108
ATZORI, F. ET AL.: "A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors", CLIN CANCER RES., vol. 17, no. 19, 2011, pages 6304 - 12
DE BONO J. S. ET AL.: "Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastaticcastration- resistant prostate cancer", CLIN CANCER RES., vol. 20, no. 7, 2014, pages 1925 - 34, XP055687495, DOI: 10.1158/1078-0432.CCR-13-1869
MARKHAM. A: "Teprotumumab: First Approval", DRUGS, vol. 80, no. 5, 2020, pages 509 - 512
RIECHMAN, L.CLARK, M.WALDMANN, H.WINTER, G.: "Reshaping human antibodies for therapy.", NATURE, vol. 332, 1988, pages 323 - 327
KABAT ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 147, no. 5, 1991, pages 1709 - 1719
AL-LAZIKANI ET AL., JOURNAL OF MOLECULAR BIOLOGY, vol. 273, no. 4, 1997, pages 927 - 948
ABHINANDAN, K.R. ET AL., MOLECULAR IMMUNOLOGY, vol. 45, 2008, pages 3832 - 3839
JIAN, Y. ET AL., NUCLEIC ACIDS RESEARCH, vol. 41, 2013, pages W34 - W40
YAMADA, T. ET AL.: "Therapeutic monoclonal antibodies", KEIO JOURNAL OF MEDICINE, vol. 60, no. 2, 2011, pages 37 - 46
BURKS, E. A. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, no. 2, 1997, pages 412 - 417
DUMET, C. ET AL., MABS, vol. 11, no. 8, 2019, pages 1341 - 1350
SAUNDERS, K. O., FRONTIERS IN IMMUNOLOGY, vol. 10, 2019, pages 1296
WALLE ET AL., EXPERT OPIN. BIOL. THER., vol. 7, no. 3, 2007, pages 405 - 418
SILVA, J-P. ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 290, no. 9, 2015, pages 5462 - 5469
"NCBI", Database accession no. NP 000609
"UniProtKB", Database accession no. P05019
"Remington: The Science and Practice of Pharmacy, 20th EDITION", 2000, LIPPINCOTT WILLIAMS & WILKINS
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495 - 497
ABUZZAHAB, M.J. ET AL.: "IGF-1 receptor mutations resulting in intrauterine and postnatal growth retardation", N ENGL J MED, vol. 349, no. 23, 2003, pages 2211 - 22
WOODS, K.A. ET AL.: "Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene", N ENGL J MED, vol. 335, no. 18, 1996, pages 1363 - 7
MUSARO, A. ET AL.: "Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle", NATURE GENETICS, vol. 27, no. 2, 2001, pages 195 - 200, XP001199471, DOI: 10.1038/84839
XIONG, L. ET AL.: "Growth-stimulatory monoclonal antibodies against human insulin-like growth factor I receptor", PROC NATL ACAD SCI USA, vol. 89, no. 12, 1992, pages 5356 - 60, XP002423617, DOI: 10.1073/pnas.89.12.5356
RUNNELS, H.A. ET AL.: "Human monoclonal antibodies to the insulin-like growth factor 1 receptor inhibit receptor activation and tumor growth in preclinical studies", ADV THER, vol. 27, no. 7, 2010, pages 458 - 75, XP002751208, DOI: 10.1007/s12325-010-0026-5
SOOS, M.A. ET AL.: "A panel of monoclonal antibodies for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity", J BIOL CHEM, vol. 267, no. 18, 1992, pages 12955 - 63, XP002477383
KATO, H. ET AL.: "Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-1) receptor. Characterization of kinase-deficient IGF-1 receptors and the action of an IGF-1-mimetic antibody (alpha IR-3).", J BIOL CHEM, vol. 268, no. 4, 1993, pages 2655 - 61, XP008114108
ATZORI, F. ET AL.: "A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors", CLIN CANCER RES., vol. 17, no. 19, 2011, pages 6304 - 12
DE BONO J. S. ET AL.: "Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastaticcastration- resistant prostate cancer", CLIN CANCER RES., vol. 20, no. 7, 2014, pages 1925 - 34, XP055687495, DOI: 10.1158/1078-0432.CCR-13-1869
MARKHAM. A: "Teprotumumab: First Approval", DRUGS, vol. 80, no. 5, 2020, pages 509 - 512
RIECHMAN, L.CLARK, M.WALDMANN, H.WINTER, G.: "Reshaping human antibodies for therapy.", NATURE, vol. 332, 1988, pages 323 - 327
KABAT ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 147, no. 5, 1991, pages 1709 - 1719
AL-LAZIKANI ET AL., JOURNAL OF MOLECULAR BIOLOGY, vol. 273, no. 4, 1997, pages 927 - 948
ABHINANDAN, K.R. ET AL., MOLECULAR IMMUNOLOGY, vol. 45, 2008, pages 3832 - 3839
JIAN, Y. ET AL., NUCLEIC ACIDS RESEARCH, vol. 41, 2013, pages W34 - W40
YAMADA, T. ET AL.: "Therapeutic monoclonal antibodies", KEIO JOURNAL OF MEDICINE, vol. 60, no. 2, 2011, pages 37 - 46
BURKS, E. A. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, no. 2, 1997, pages 412 - 417
DUMET, C. ET AL., MABS, vol. 11, no. 8, 2019, pages 1341 - 1350
SAUNDERS, K. O., FRONTIERS IN IMMUNOLOGY, vol. 10, 2019, pages 1296
WALLE ET AL., EXPERT OPIN. BIOL. THER., vol. 7, no. 3, 2007, pages 405 - 418
SILVA, J-P. ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 290, no. 9, 2015, pages 5462 - 5469
"NCBI", Database accession no. NP 000609
"UniProtKB", Database accession no. P05019
"Remington: The Science and Practice of Pharmacy, 20th EDITION", 2000, LIPPINCOTT WILLIAMS & WILKINS
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495 - 497
Attorney, Agent or Firm:
AOKI, Atsushi et al. (JP)
Download PDF: